Skip to Main Content

Author Details

Susana Miranda
The Institute of Cancer Research
2008
56
36
PMIDPaper TitleJournal TitlePublished Year
36114082B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.Eur Urol2023
37652207Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.Lab Invest2023
37284046Germline <i>ATM</i> Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer.Eur Urol Open Sci2023
36964041Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38].Eur Urol2023
36609007A Transgender Patient with Prostate Cancer: Lessons Learnt.Eur Urol2023
35552383Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate Cancer.Clin Cancer Res2022
35491356Immune Biomarkers in Metastatic Castration-resistant Prostate Cancer.Eur Urol Oncol2022
35717027Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors.J Immunother Cancer2022
32988971Characterizing CDK12-Mutated Prostate Cancers.Clin Cancer Res2021
33822745JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate Cancer.Cancer Res2021
33549985Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit Experience.Cancer Treat Res Commun2021
34753775HER3 Is an Actionable Target in Advanced Prostate Cancer.Cancer Res2021
34045297Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.Cancer Discov2021
34084213HER3 expression and MEK activation in non-small-cell lung carcinoma.Lung Cancer Manag2021
33176972Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.Eur Urol2021
32532747Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i>- and Non-<i>BRCA1/2</i>-Mutant Cancers.Cancer Discov2020
31874108Genomics of lethal prostate cancer at diagnosis and castration resistance.J Clin Invest2020
31806540Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.Lancet Oncol2020
32169873Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.J Immunother Cancer2020
30340782Genomic Analysis of Three Metastatic Prostate Cancer Patients with Exceptional Responses to Carboplatin Indicating Different Types of DNA Repair Deficiency.Eur Urol2019
30257982RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer.Clin Cancer Res2019
31152158Publisher Correction: The long tail of oncogenic drivers in prostate cancer.Nat Genet2019
31036442Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.Eur Urol2019
31061129Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019
29741566Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.Ann Oncol2018
29911685Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers.Eur Urol Oncol2018
30179225Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
30068710SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity.Clin Cancer Res2018
30042009Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer.Clin Colorectal Cancer2018
30093450Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis.Clin Cancer Res2018
30382943Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.J Clin Invest2018
29610475The long tail of oncogenic drivers in prostate cancer.Nat Genet2018
28751446Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification.Clin Cancer Res2017
28450425Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.Cancer Discov2017
27246360Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses.Clin Genitourin Cancer2016
27197266Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells.Cancer Res2016
27289566Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.Eur Urol2016
25041380Sarcomatoid carcinoma of the prostate: ERG fluorescence in-situ hybridization confirms epithelial origin.Histopathology2015
28843286Integrative Clinical Genomics of Advanced Prostate Cancer.Cell2015
26510020DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.N Engl J Med2015
26379078PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients.Br J Cancer2015
26085511Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration.Clin Cancer Res2015
26000489Integrative clinical genomics of advanced prostate cancer.Cell2015
25719830Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.Br J Cancer2015
25454616PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.Eur Urol2015
24634505Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.J Natl Cancer Inst2014
25232177Tumor clone dynamics in lethal prostate cancer.Sci Transl Med2014
23524863Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.Ann Oncol2013
24185264Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.Oncotarget2013
24169353First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.Br J Cancer2013
  • 1 - 50 of 56

Recommended Authors

Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 21
George V Thomas
Knight Cancer Institute, Oregon Health and Science University
Career Start Year 2016
Number of shared co-authors 4
Pedro Isaacsson Velho
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Career Start Year 2013
Number of shared co-authors 7
Matti Annala
University of British Columbia
Career Start Year 2011
Number of shared co-authors 14
Adam G Sowalsky
National Cancer Institute
Career Start Year 2010
Number of shared co-authors 21
Alexander W Wyatt
University of British Columbia
Career Start Year 2007
Number of shared co-authors 27
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 30
Arun A Azad
Peter MacCallum Cancer Centre
Career Start Year 2007
Number of shared co-authors 9
Alan H Bryce
Mayo Clinic
Career Start Year 2006
Number of shared co-authors 13
Tamara L Lotan
Johns Hopkins University School of Medicine
Career Start Year 2006
Number of shared co-authors 40
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 9
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 31
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 15
Ladan Fazli
University of British Columbia
Career Start Year 2002
Number of shared co-authors 19
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 18
Mark C Markowski
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2001
Number of shared co-authors 6
David T Miyamoto
Massachusetts General Hospital
Career Start Year 2000
Number of shared co-authors 6
Eleni Efstathiou
Houston Methodist Cancer Center
Career Start Year 2000
Number of shared co-authors 24
Kim N Chi
University of British Columbia
Career Start Year 2000
Number of shared co-authors 36
Emmanuel S Antonarakis
The Sidney Kimmel Cancer Comprehensive Cancer Center at Johns Hopkins
Career Start Year 2000
Number of shared co-authors 44
Yuzhuo Wang
University of British Columbia
Career Start Year 2000
Number of shared co-authors 28
Martijn P Lolkema
Erasmus MC Cancer Institute
Career Start Year 1999
Number of shared co-authors 8
Joshi J Alumkal
Rogel Cancer Center, University of Michigan ann arbor
Career Start Year 1999
Number of shared co-authors 39
Hayley C Whitaker
University College London
Career Start Year 1999
Number of shared co-authors 14
Srinivasan Yegnasubramanian
Johns Hopkins University School of Medicine
Career Start Year 1999
Number of shared co-authors 20
Anthony M Joshua
The Kinghorn Cancer Centre, St. Vincent's Hospital Sydney
Career Start Year 1997
Number of shared co-authors 17
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 21
Phuoc T Tran
University of Maryland School of Medicine
Career Start Year 1996
Number of shared co-authors 9
Edwin M Posadas
Cedars-Sinai Medical Center
Career Start Year 1993
Number of shared co-authors 19
David I Quinn
USC Norris Comprehensive Cancer Center
Career Start Year 1993
Number of shared co-authors 14

Collaborators

Johann S de Bono
The Institute for Cancer Research
Co-authored papers 52
Suzanne Carreira
The Institute of Cancer Research
Co-authored papers 33
Wei Yuan
The Institute for Cancer Research
Co-authored papers 27
Nina Tunariu
The Institute of Cancer Research
Co-authored papers 27
Joaquin Mateo
Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital Campus
Co-authored papers 25
Adam Sharp
The Institute for Cancer Research
Co-authored papers 20
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 17
Zafeiris Zafeiriou
Theageneion Anticancer Hospital
Co-authored papers 16
Penny Flohr
The Institute of Cancer Research
Co-authored papers 14
Roberta Ferraldeschi
Astex Pharmaceuticals
Co-authored papers 13
Dan R Robinson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 10
Howard I Scher
Memorial Sloan Kettering Cancer Center
Co-authored papers 10
Gunther Boysen
Co-authored papers 10
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 10
Raquel Perez-Lopez
Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus
Co-authored papers 10
Mark A Rubin
University of Bern
Co-authored papers 9
Alec Paschalis
The Institute for Cancer Research
Co-authored papers 9
Colin C Pritchard
University of Washington, USA Brotman Baty Institute for Precision Medicine
Co-authored papers 8
Matthew Clarke
Co-authored papers 8
Maryou B Lambros
The Institute of Cancer Research
Co-authored papers 8
Charles L Sawyers
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Peter S Nelson
Fred Hutchinson Cancer Center
Co-authored papers 7
Mary-Ellen Taplin
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Co-authored papers 7
Nikolaus Schultz
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Eliezer M Van Allen
Dana-Farber Cancer Institute
Co-authored papers 7
Himisha Beltran
Dana-Farber Cancer Institute
Co-authored papers 7
Francesca Demichelis
University of Trento
Co-authored papers 7
Yi-Mi Wu
University of Michigan Medical School ann arbor
Co-authored papers 7
Wassim Abida
Memorial Sloan Kettering Cancer Center
Co-authored papers 7
Stephen R Plymate
University of Washington
Co-authored papers 6
Release 1.2